Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexarotene add-on in schizophrenia
NCT00141947Phase 3Unknown
- Sponsor
- Be'er Sheva Mental Health Center
- Start
- Sep 2005
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bexarotene in schizophrenia, sponsored by Be'er Sheva Mental Health Center. Primary endpoints: Schedule for Assessment of Mental Disorder at 6 weeks, The Positive and Negative Syndrome Scale at 6 weeks and 1 more. Status: unknown.
02
Drugs
bexarotene
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00141947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00141947.